Key facts
- This page summarizes Jeffrey S. Hackman's Form 4/A - Amendment filing for FENNEC PHARMACEUTICALS INC. (FENC).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Apr 2025, 19:13.
Jeffrey S. Hackman - 28 Mar 2025 Form 4/A - Amendment Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- FENC
- Reported as of
- 28 Mar 2025
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 03 Apr 2025, 19:13:43 UTC
- Original report date
- 03 Apr 2025
- Prior SEC filing
- 19 Aug 2024
- Next SEC filing
- 19 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Hackman
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey S. Hackman filed Form 4/A - Amendment for FENNEC PHARMACEUTICALS INC. (FENC) on 03 Apr 2025.
Change
- Previous filing in this sequence was filed on 19 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FENC
transaction
Derivative
Restricted Share Unit
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- +19%
- Price
- $0.000000
- Shares after
- 475,000
- Date
- 28 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 75,000
- Exercise price
- $0.000000
- Footnotes
- F1, F2
FENC
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- +11%
- Price
- $0.000000
- Shares after
- 525,000
- Date
- 28 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 50,000
- Exercise price
- $6.50
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On March 28, 2025, Jeffrey Hackman was awarded restricted share units to acquire 75,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan
Footnote F2
One-third of the shares subject to this award shall be released from restriction as of March 28, 2026 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction.
Footnote F3
On March 28, 2025, Jeffrey Hackman was granted incentive stock options to purchase 50,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
Footnote F4
One-third of the shares subject to this option may be exercised as of March 28, 2026 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028, 100% of the total number of shares subject to this option shall be vested